Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APACHE-AF trial of apixaban versus antiplatelet therapy or no antithrombotic therapy after anticoagulation-associated intracerebral hemorrhage in atrial fibrillation
NL-OMON50507Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Composite of vascular death or non-fatal stroke. Started Jan 2015; status: active, not recruiting.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON50507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50507.